Response to pazopanib‐based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma

Angiogenesis inhibitors (AGI) are not presently used for the treatment of gastric cancers. This report demonstrates that angiogenesis inhibitor can be safely and effectively used in combination with cytotoxic anti‐cancer agents for treatment of Gastric cancers.

Detalles Bibliográficos
Autores principales: Limaye, Sewanti, Patil, Darshana, Akolkar, Dadasaheb, Srivastava, Navin, Patil, Revati, Apurwa, Sachin, Patil, Sanket, John, Jinumary, Gosavi, Rahul, Nesargikar, Prabhu, Kumar, Prashant, Datta, Vineet, Bose, Chirantan, Raazi, Zarrine, Srinivasan, Ajay, Datar, Rajan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572349/
https://www.ncbi.nlm.nih.gov/pubmed/34765202
http://dx.doi.org/10.1002/ccr3.4986
Descripción
Sumario:Angiogenesis inhibitors (AGI) are not presently used for the treatment of gastric cancers. This report demonstrates that angiogenesis inhibitor can be safely and effectively used in combination with cytotoxic anti‐cancer agents for treatment of Gastric cancers.

Ejemplares similares